Soluble galectin-3 is associated with premature myocardial infarction

European Journal of Clinical Investigation

Volumn 46, Issue 5, 2016, Pages 386-391

  Winter, Max Paul ^a   Wiesbauer, Franz ^a   Alimohammadi, Arman ^a   Blessberger, Hermann ^b   Pavo, Noemi ^a   Schillinger, Martin ^a   Huber, Kurt ^c   Wojta, Johann ^a,d   Lang, Irene M ^a   Maurer, Gerald ^a   Goliasch, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Galectin 3; Inflammation; Premature coronary artery disease

Indexed keywords

GALECTIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL; GALECTIN-3, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL LIPASE;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RISK FACTOR; SURVIVOR; ATHEROSCLEROTIC PLAQUE; BLOOD; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; HYPERTENSION; MYOCARDIAL INFARCTION; SMOKING; STATISTICAL MODEL;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GALECTIN 3; HUMANS; HYPERTENSION; LEUKOCYTE COUNT; LIPASE; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; SMOKING;

EID: 84960921313     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12605     Document Type: Article

References (33)

1. Rallidis LS, Sakadakis EA, Tympas K, Varounis C, Zolindaki M, Dagres N et al. The impact of smoking on long-term outcome of patients with premature (
2. Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (
3. Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS. Long-term follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol 2003;41:521-8.
4. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18 to 39 years of age. Ann Intern Med 2001;134:433-9.
5. Distelmaier K, Wiesbauer F, Blessberger H, Oravec S, Schrutka L, Binder C et al. Impaired antioxidant HDL function is associated with premature myocardial infarction. Eur J Clin Invest 2015;45:731-8.
6. Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). Eur Heart J 2009;30:1073-9.
7. Bajaj S, Shamoon F, Gupta N, Parikh R, Parikh N, Debari VA et al. Acute ST-segment elevation myocardial infarction in young adults: who is at risk? Coronary Artery Dis 2011;22:238-44.
8. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Int Med 2015;278:483-93.
9. Pineda J, Marin F, Roldan V, Valencia J, Marco P, Sogorb F. Premature myocardial infarction: clinical profile and angiographic findings. Int J Cardiol 2008;126:127-9.
10. Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost 2009;101:1006-11.
11. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905-13.
12. Shah PK. Biomarkers of plaque instability. Curr Cardiol Rep 2014;16:547.
13. Szadkowska I, Wlazel RN, Migala M, Szadkowski K, Zielinska M, Paradowski M et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J 2013;20:577-82.
14. Arar C, Gaudin JC, Capron L, Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 1998;430:307-11.
15. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8.
16. Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015;35:725-32.
17. Goliasch G, Wiesbauer F, Grafl A, Ponweiser E, Blessberger H, Tentzeris I et al. The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (
18. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 2007;53:940-6.
19. Oberaigner W, Siebert U. Are survival rates for Tyrol published in the Eurocare studies biased? Acta Oncol 2009;48:984-91.
20. Meijers WC, van der Velde AR, Pascual-Figal DA, de Boer RA. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol 2015;763:115-21.
21. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008;172:247-55.
22. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998;152:1199-208.
23. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008;28:433-40.
24. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000;165:2156-64.
25. Kadoglou NP, Sfyroeras GS, Spathis A, Gkekas C, Gastounioti A, Mantas G et al. Galectin-3, carotid plaque vulnerability, and potential effects of statin therapy. Eur J Vasc Endovasc Surg 2015;49:4-9.
26. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22.
27. Ertelt K, Genereux P, Mintz GS, Brener SJ, Kirtane AJ, McAndrew TC et al. Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovasc Revasc Med 2014;15:375-80.
28. Goliasch G, Wiesbauer F, Blessberger H, Demyanets S, Wojta J, Huber K et al. Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. J Clin Lipidol 2015;9:801-6. e1.
29. MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013;23:654-63.
30. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29:831-6.
31. Kataoka Y, Puri R, Nicholls SJ. Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. Cardiovasc Diagn Ther 2015;5:280-9.
32. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
33. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000;21:1406-32.